Itf Pharma Gmbh

Itf Pharma Gmbh company information, Employees & Contact Information

Explore related pages

Related company profiles:

ITF Pharma GmbH, based in Munich, Germany, is the German corporate headquarters of the Italfarmaco Group. Italfarmaco S.p.A., a family-owned company based in Milan, Italy, is a multinational pharmaceutical company that produces and distributes modern, highly effective preparations in the fields of gynecology, cardiology, oncology and neurology. Since the 1990s, the Italfarmaco Group has entered numerous foreign markets. This internationalization has been driven both by distribution, representation and authorization agreements and by the creation of its own subsidiaries. Today, the Italfarmaco Group is present in over 50 countries. Since 2019, the Italfarmaco Group has been operating on the German market with ITF Pharma GmbH, offering pioneering medical supplies and customized services here as well. More than 75 employees work full of passion and enthusiasm for a better medicine of tomorrow. With the foundation of ITF Pharma GmbH, doctors and patients now have a reliable partner in the field of women's health in Germany as well.

Company Details

Employees
102
Founded
-
Address
Prinzregentenplatz 14, Munich,bavaria 81675,germany
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Munich, Bavaria
Looking for a particular Itf Pharma Gmbh employee's phone or email?

Itf Pharma Gmbh Questions

News

ITF Therapeutics LLC Announces Opening of New U.S. Headquarters in Concord, Massachusetts - PR Newswire

ITF Therapeutics LLC Announces Opening of New U.S. Headquarters in Concord, Massachusetts PR Newswire

Italfarmaco’s Duvyzat backed by MHRA - The Pharma Letter

Italfarmaco’s Duvyzat backed by MHRA The Pharma Letter

MHRA approves Italfarmaco’s Duvyzat to treat Duchenne muscular dystrophy - PMLiVE

MHRA approves Italfarmaco’s Duvyzat to treat Duchenne muscular dystrophy PMLiVE

ITF Therapeutics Appoints Erica L. Monaco, CPA, as Chief Operating Officer - citybiz

ITF Therapeutics Appoints Erica L. Monaco, CPA, as Chief Operating Officer citybiz

ITF Therapeutics LLC Announces Appointment of Erica L. Monaco, CPA, as Chief Operating Officer - PR Newswire

ITF Therapeutics LLC Announces Appointment of Erica L. Monaco, CPA, as Chief Operating Officer PR Newswire

ITF Gears Up for FDA Decision in Expanding DMD Market - BioSpace

ITF Gears Up for FDA Decision in Expanding DMD Market BioSpace

ITF Pharma of Berwyn launches ALS drug - The Business Journals

ITF Pharma of Berwyn launches ALS drug The Business Journals

FDA clears first-of-its-kind Duchenne drug for broad use - BioPharma Dive

FDA clears first-of-its-kind Duchenne drug for broad use BioPharma Dive

Italfarmaco nabs FDA approval for new Duchenne med, teeing up sparring match with Sarepta - Fierce Pharma

Italfarmaco nabs FDA approval for new Duchenne med, teeing up sparring match with Sarepta Fierce Pharma

ITF Therapeutics LLC Announces U.S. Commercial Availability of DUVYZAT™ (givinostat) for Treatment of Patients With Duchenne Muscular Dystrophy - BioSpace

ITF Therapeutics LLC Announces U.S. Commercial Availability of DUVYZAT™ (givinostat) for Treatment of Patients With Duchenne Muscular Dystrophy BioSpace

Starpharma licenses US rights to VivaGel BV - BiotechDispatch

Starpharma licenses US rights to VivaGel BV BiotechDispatch

ITF Pharma Announces FDA Approval of Supplemental New Drug Application (sNDA) for TIGLUTIK® (riluzole) Oral Suspension For The Treatment Of Amyotrophic Lateral Sclerosis (ALS) with a Percutaneous Endoscopic Gastrostomy (PEG) Feeding Tube - PR Newswire

ITF Pharma Announces FDA Approval of Supplemental New Drug Application (sNDA) for TIGLUTIK® (riluzole) Oral Suspension For The Treatment Of Amyotrophic Lateral Sclerosis (ALS) with a Percutaneous Endoscopic Gastrostomy (PEG) Feeding Tube PR Newswire

ITF Pharma Receives Patient Impact Award for First and Only Easy-To-Swallow Thickened Liquid Treatment for Amyotrophic Lateral Sclerosis (ALS) - PR Newswire

ITF Pharma Receives Patient Impact Award for First and Only Easy-To-Swallow Thickened Liquid Treatment for Amyotrophic Lateral Sclerosis (ALS) PR Newswire

Top Itf Pharma Gmbh Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant